<h1>New U.S. tariffs including 100% drug duties from October 1 pose legal, WTO, and trade-partner exemption challenges</h1> A U.S. administration announcement of new tariffs, including 100% duties on imported pharmaceuticals effective October 1, raises immediate legal and trade-policy issues: whether new levies will layer atop existing duties, how 'national security' is being invoked as a WTO-compatible justification, and whether trade-partner exemptions under existing agreements will apply. The move creates uncertainty for foreign exporters and supply chains, may trigger retaliatory measures or litigation under domestic and international trade law, and is affecting global markets and negotiations as affected jurisdictions consider responses and potential challenges.